Reductions in cholinergic function in the EC is one of the earliest manifestations of AD (Hampel et al., 2018), and we therefore assessed the effects of hAβ1–42 on the expression of the vesicular acetylcholine transporter (VAChT) and the degradative enzyme acetylcholinesterase (AChE). This evidence concerns the gene SLC18A3 and Alzheimer disease.